Search results for "pharmacokinetic"

showing 10 items of 474 documents

Polypharmacy and the risk of drug-drug interactions and potentially inappropriate medications in hospital psychiatry.

2021

PURPOSE The aim of this study was to analyze the epidemiology of polypharmacy in hospital psychiatry. Another aim was to investigate predictors of the number of drugs taken and the associated risks of drug-drug interactions and potentially inappropriate medications in the elderly. METHODS Daily prescription data were obtained from a pharmacovigilance project sponsored by the Innovations Funds of the German Federal Joint Committee. RESULTS The study included 47 071 inpatient hospital cases from eight different study centers. The mean number of different drugs during the entire stay was 6.1 (psychotropic drugs = 2.7; others = 3.4). The mean number of drugs per day was 3.8 (psychotropic drugs …

DrugMalemedicine.medical_specialtyEpidemiologymedia_common.quotation_subjectInappropriate Prescribing030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicinePharmacokineticsPharmacovigilanceEpidemiologyMedicineHumansPharmacology (medical)Drug Interactions030212 general & internal medicineRisk factorPsychiatryPotentially Inappropriate Medication Listmedia_commonAgedPolypharmacyPsychiatrybusiness.industryPharmacoepidemiologyHospitalsPsychotropic drugPharmaceutical PreparationsPolypharmacyFemalebusinessPharmacoepidemiology and drug safetyREFERENCES
researchProduct

Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Nifedipine

2015

Literature data relevant to the biopharmaceutical properties of the active pharmaceutical ingredient (API) nifedipine are reviewed to evaluate whether a waiver of in vivo bioequivalence (BE) testing of immediate-release (IR) dosage forms formulated as tablets and soft gelatin capsules is warranted. Nifedipine's solubility and permeability, its therapeutic use and index, pharmacokinetics, food drug interactions, and any reported BE/bioavailability problems were all taken into consideration. Solubility and BA data indicate conclusively that nifedipine is a class II substance of biopharmaceutics classification system (BCS) and that the formulation of drug product plays a key role on the dissol…

DrugNifedipineChemistry Pharmaceuticalmedia_common.quotation_subjectPharmaceutical ScienceCapsulesBioequivalencePharmacologyDosage formExcipientsFood-Drug InteractionsNifedipinePharmacokineticsmedicineAnimalsHumansmedia_commonActive ingredientChemistryCalcium Channel BlockersBiopharmaceutics Classification SystemBioavailabilityIntestinal AbsorptionSolubilityTabletsmedicine.drugJournal of Pharmaceutical Sciences
researchProduct

Response to Agomelatine Treatment is Independent of Smoking Status and Dosage: Results From the AGOPSYCH Study.

2018

Abstract Introduction Cigarette smoking influences response to antidepressant treatment. It accelerates the metabolism of several cytochrome P450 (CYP) subtypes, including CYP1A2, and therefore bears the risk of pharmacokinetic interactions with psychotropic drugs using that pathway. Agomelatine is a substrate of CYP1A2; the association between nicotine use and agomelatine dosage, however, has never been studied before. Methods Smoking habits were correlated with agomelatine doses and treatment outcomes in a sample of 27 patients with lifetime diagnoses within the schizophrenia spectrum who received agomelatine treatment in addition to their stable antipsychotic treatment regimen because of…

DrugOncologyAdultMalemedicine.medical_specialtymedia_common.quotation_subject030226 pharmacology & pharmacyNicotine03 medical and health sciencesYoung Adult0302 clinical medicinePharmacokineticsInternal medicineAcetamidesmedicineAgomelatineHumansPharmacology (medical)Young adultmedia_commonPsychiatric Status Rating ScalesDose-Response Relationship Drugbusiness.industryDepressionSmokingGeneral MedicineMiddle Agedmedicine.diseaseAntidepressive Agents030227 psychiatry3. Good healthPsychiatry and Mental healthRegimenTreatment OutcomeSchizophreniaAntidepressantFemalebusinessmedicine.drugPharmacopsychiatry
researchProduct

A multilevel object-oriented modelling methodology for physiologically-based pharmacokinetics (PBPK): Evaluation with a semi-mechanistic pharmacokine…

2019

Abstract Background and objective The aims of this study are (i) to assess the predictive reliability of the physiologically based software PhysPK versus the well-known population approach software NONMEM for the cited semi-mechanistic PK model, (ii) to determine whether these modelling approaches are interchangeable and (iii) to compare acausal with causal modelling approaches in the framework of semi-mechanistic PK models. Methods A semi-mechanistic model was proposed, which assumed oral administration of a solid dosage form with a peripheral compartment and two active metabolites. The model incorporates intestinal transit, dissolution limited by solubility, variable efflux transporter ex…

DrugPhysiologically based pharmacokinetic modellingComputer sciencemedia_common.quotation_subjectPopulationCmaxHealth InformaticsModels BiologicalDosage form030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineSoftwarePharmacokineticsPharmacokineticseducationmedia_commonVariable (mathematics)education.field_of_studybusiness.industryReproducibility of ResultsExpression (computer science)Computer Science ApplicationsNONMEMSolubilityArea Under CurvebusinessBiological system030217 neurology & neurosurgerySoftwareComputer methods and programs in biomedicine
researchProduct

Biopartitioning micellar separation methods: modelling drug absorption

2003

The search for new pharmacologically active compounds in drug discovery programmes often neglects biopharmaceutical properties as drug absorption. As a result, poor biopharmaceutical characteristics constitute a major reason for the low success rate for candidates in clinical development. Since the cost of drug development is many times larger than the cost of drug discovery, predictive methodologies aiding the selection of bioavailable drug candidates are of profound significance. This paper has been focussed on recent developments and applications of chromatographic systems, particularly those systems based on amphiphilic structures, in the frame of alternative approaches for estimating t…

DrugQuantitative structure–activity relationshipCell Membrane PermeabilityChromatographyChemistryDrug discoverymedia_common.quotation_subjectClinical BiochemistryQuantitative Structure-Activity RelationshipCell BiologyGeneral MedicineHealth economyBiochemistryAnalytical ChemistryPassive permeabilityBiopharmaceuticalDrug developmentSeparation methodPharmacokineticsMicellesmedia_commonJournal of Chromatography B
researchProduct

Ketamine in acute phase of severe traumatic brain injury “an old drug for new uses?”

2021

AbstractMaintaining an adequate level of sedation and analgesia plays a key role in the management of traumatic brain injury (TBI). To date, it is unclear which drug or combination of drugs is most effective in achieving these goals. Ketamine is an agent with attractive pharmacological and pharmacokinetics characteristics. Current evidence shows that ketamine does not increase and may instead decrease intracranial pressure, and its safety profile makes it a reliable tool in the prehospital environment. In this point of view, we discuss different aspects of the use of ketamine in the acute phase of TBI, with its potential benefits and pitfalls.

DrugSecondary insultmedicine.medical_specialtyTime FactorsIntracranial PressureTraumatic brain injurySedationmedia_common.quotation_subjectCritical Care and Intensive Care MedicineNeuroprotectionCooperative sedation03 medical and health sciencesViewpointTraumatic brain injury0302 clinical medicinePharmacokineticsBrain Injuries TraumaticmedicineHumansHypnotics and SedativesKetamineIntensive care medicineIntracranial pressuremedia_commonAnesthetics DissociativeAgitationbusiness.industrylcsh:Medical emergencies. Critical care. Intensive care. First aid030208 emergency & critical care medicinelcsh:RC86-88.9medicine.diseaseNeuroprotectionSafety profileSedationKetaminemedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugCritical Care
researchProduct

Isosorbide dinitrate: pharmacokinetics after intravenous administration.

1982

Isosorbide dinitrate (ISDN) is an important organic nitrate found therapeutically useful in its sublingual and oral forms in various cardiovascular diseases such as angina pectoris (1) and congestive heart failure (2). Recently Distante et al. (3) showed that an intravenous infusion of this drug, at 0.021–0.083 mg/min is also effective in managing unstable angina. The availability of an intravenous dosage form of ISDN not only affords the opportunity to characterize the pharmacokinetics of this drug after this particular mode of therapy, but also gives the possibility of assessing the bio-availability of this drug after other (e.g., oral) routes of administration in patients. This latter po…

DrugUnstable anginabusiness.industrymedia_common.quotation_subjectPharmaceutical ScienceIsosorbide Dinitratemedicine.diseaseDosage formAngina PectorisAnginaKineticsPharmacokineticsHeart failureAnesthesiamedicineHumansIn patientInfusions ParenteralIsosorbide dinitratebusinessmedia_commonmedicine.drugJournal of pharmaceutical sciences
researchProduct

Interacciones farmacológicas de los fármacos antihipertensivos

2005

A drug interaction is the quantitative or qualitative modification of the effect of a drug by the simultaneous or successive administration of a different one. Hypertensive patients, mainly the more elderly ones, frequently present concomitant diseases that require the administration of several medicines which facilitates the appearance of interactions. The lack of effectiveness of the antihypertensive treatment is a relatively frequent fact that sometimes is due to interactions of antihypertensive drugs with other treatments. It is difficult to determine the incidence of interactions, but it is related to the number of drugs administered simultaneously. Between 37 and 60% of hospital-admis…

Drugbiologybusiness.industrymedia_common.quotation_subjectCytochrome P450Angiotensin-converting enzymeGeneral MedicineDrug interactionBioinformaticsPharmacokineticsbiology.proteinMedicineIn patientAngiotensin Receptor Blockersbusinessmedia_commonMedicina Clínica
researchProduct

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Aciclovir

2008

Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing (biowaiver) for the approval of immediate release (IR) solid oral dosage forms containing aciclovir are reviewed. Aciclovir therapeutic use and therapeutic index, pharmacokinetic properties, data related to the possibility of excipient interactions and reported BE/bioavailability (BA) studies were also taken into consideration in order to ascertain whether a biowaiver can be recommended. According to the Biopharmaceutics Classification System (BCS) and considering tablet strengths up to 400 mg, aciclovir would be BCS Class III. However, in some countries also 800 mg tablets are available which …

Drugbusiness.industrymedia_common.quotation_subjectAcyclovirAdministration OralBiological Availabilityvirus diseasesPharmaceutical ScienceExcipientPharmacologyBioequivalenceBiopharmaceutics Classification SystemAntiviral AgentsDosage formTherapeutic EquivalencyPharmacokineticsmedicineRegulatory scienceAciclovirbusinessmedicine.drugmedia_commonJournal of Pharmaceutical Sciences
researchProduct

Influence of Chemical Enhancers and Iontophoresis on the In Vitro Transdermal Permeation of Propranolol: Evaluation by Dermatopharmacokinetics

2018

[EN] The aims of this study were to assess, in vitro, the possibility of administering propranolol transdermally and to evaluate the usefulness of the dermatopharmacokinetic (DPK) method in assessing the transport of drugs through stratum corneum, using propranolol as a model compound. Four chemical enhancers (decenoic and oleic acid, laurocapram, and R-(+)-limonene) and iontophoresis at two current densities, 0.25 and 0.5 mA/cm(2) were tested. R-(+)-limonene, and iontophoresis at 0.5 mA/cm(2) were proven to be the most efficient in increasing propranolol transdermal flux, both doubled the original propranolol transdermal flux. Iontophoresis was demonstrated to be superior than the chemical…

Drugdermatopharmacokineticsmedia_common.quotation_subjectChemical enhancerslcsh:RS1-441Pharmaceutical SciencePropanol - Uso terapéutico.02 engineering and technologyPropranololMedicamentos - Administración.030226 pharmacology & pharmacyArticlelcsh:Pharmacy and materia medicaIonización.03 medical and health sciences0302 clinical medicineIonization.medicineStratum corneumpropranololDermatopharmacokineticsTransdermalmedia_commonchemical enhancersChromatographytransdermal administrationIontophoresisChemistryLaurocapramTransdermal administrationIontophoresisDrugs - Administration.Skin absorption.iontophoresisPermeation021001 nanoscience & nanotechnologyPropranololPropanol - Therapeutic use.In vitromedicine.anatomical_structurePropanol - Pharmacokinetics.Propanol - Farmacocinética.Absorción cutánea.0210 nano-technologymedicine.drugPharmaceutics
researchProduct